Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf · PHASE3 · terminated · last registry update 2026-01-05 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.” | – | Registry record, Universitätsklinikum Hamburg-Eppendorf |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision